6,700 results match your criteria Acta Haematologica[Journal]


Successful treatment of the TEMPI syndrome with pomalidomide plus dexamethasone followed by autologous stem cell transplantation.

Acta Haematol 2022 May 23. Epub 2022 May 23.

TEMPI syndrome is a rare disease associated with plasma cell neoplasms. Although previous studies have reported that bortezomib is effective as a 1st-line treatment for TEMPI syndrome, some cases are refractory to this treatment. Pomalidomide, a kind of immunomodulatory drugs, is widely used for the treatment of relapsed or refractory multiple myeloma and could be administered without dose modification in patients with renal dysfunction. Read More

View Article and Full-Text PDF

Tanshinone IIA inhibits tissue factor expression induced by thrombin in human umbilical vein endothelial cells via PAR-1 and p38 MAPK signaling pathway.

Acta Haematol 2022 May 20. Epub 2022 May 20.

Background: The potential signaling pathway of TSA suppressing TF expression induced by thrombin was unknown. Thus, the transcription of TF in HUVECs, and the expressions of DCF, phospho-p38 MAPK, NADPH oxidase 4, PAR-1 and NF-B were detected in our study.

Methods: HUVECs were randomly divided into control group, thrombin treated group (with 5 U/ml of thrombin) and 4 TSA treated groups (with 5 U/ml of thrombin plus TSA with 4 different concentrations of 1 μg/ml, 10 μg/ml, 100 μg/ml and 1 mg/ml respectively). Read More

View Article and Full-Text PDF

Gilteritinib in isolated breast relapse of FLT3positive acute myeloid leukemia: a case report and review of literature.

Acta Haematol 2022 May 17. Epub 2022 May 17.

Extramedullary relapse of acute myeloid leukemia (AML) is not a rare event and FMS-like tyrosine kinase 3 (FLT3) mutation is a well-known risk factor. Gilteritinib is approved for relapsed/refractory FLT3+ AML but its efficacy in extramedullary relapse is still undefined. Here, we present the case of a 69-year-old woman with therapy-related nucleophosmin-1 (NPM1) and FLT3-internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia treated with induction and consolidation with CPX-351 (liposomal daunorubicin plus cytarabine) followed by off-label azacitidine maintenance who obtained a complete remission (CR) with persistent measurable residual disease. Read More

View Article and Full-Text PDF

Acquired Factor V Deficiency: A New Cause of Bleeding in Patients with Chronic Myeloid Leukemia and Extreme Leukocytosis?

Acta Haematol 2022 May 2. Epub 2022 May 2.

Bleeding complications in patients with MPNs are known to be related to acquired von Willebrand disease or platelet dysfunction. Here, we describe two very similar cases of chronic-phase CML with extreme leukocytosis (>500,000/mcL) and deep tissue bleeding after a minor trauma, who had increased PT and PTT, normal VWF antigen and activity. The patients were found to have acquired factor V deficiency. Read More

View Article and Full-Text PDF

COVID-19 Coagulopathy: From Pathogenesis to Treatment.

Acta Haematol 2022 Feb 8:1-15. Epub 2022 Feb 8.

Department of Internal Medicine, Vascular Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.

Coronavirus disease 2019 (COVID-19) has emerged as a pandemic at the end of 2019 and continues to exert an unfavorable worldwide health impact on a large proportion of the population. A remarkable feature of COVID-19 is the precipitation of a hypercoagulable state, mainly in severe cases, leading to micro- and macrothrombosis, respiratory failure, and death. Despite the implementation of various therapeutic regimes, including anticoagulants, a large number of patients suffer from such serious complications. Read More

View Article and Full-Text PDF
February 2022

A systematic review assessing the under-representation of cancer patients in COVID-19 trials.

Acta Haematol 2022 Apr 21. Epub 2022 Apr 21.

Background - The new severe acute respiratory syndrome coronavirus 2 have emerged as a global pandemic that threatens thousands around the world. Observational cohort studies have demonstrated that cancer patients have inferior outcomes due to underlying malignancy, treatment-related immunosuppression, or increased comorbidities. We aimed to examine the representation of cancer patients (hematological malignancies and solid tumors) in COVID-19 therapeutic and prophylactic interventional trials. Read More

View Article and Full-Text PDF

Small RNA SequencingReveals Exosomal miRNAs as Unique Feature Markers in Unprovoked Venous Thromboembolism.

Acta Haematol 2022 Apr 19. Epub 2022 Apr 19.

Introduction: Venous thromboembolism (VTE) is a common cardiovascular disease. miRNAs play a key role in VTE; however, the role of exosomal miRNAs in VTE remains unknown. Therefore, we aimed to identify key exosomal miRNAs and their potential mechanisms in VTE. Read More

View Article and Full-Text PDF

The Association between P-Selectin Autoantibody Positive and Response to Steroid Treatment in Newly Diagnosed Immune Thrombocytopenia Patients.

Acta Haematol 2022 Apr 11. Epub 2022 Apr 11.

Objective: This study aimed to detect the association between P-selectin autoantibody positive and response to steroid treatment in newly diagnosed immune thrombocytopenia (ITP) patients.

Methods: The data from 105 newly diagnosed adult ITP patients administered with first-line of steroid treatment from October 2016 to May 2021 were retrospectively analyzed. Treatment responses were evaluated within 3 months after the onset of treatment. Read More

View Article and Full-Text PDF

Myeloid Neoplasm with PCM1-PDGFRB Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review.

Acta Haematol 2022 Mar 25. Epub 2022 Mar 25.

Through an RNA-seq analysis of an adult patient with unclassifiable myelodysplastic/ myeloproliferative neoplasms (MDS/MPN-U), we identified a rare PDGFRB fusion partner gene, PCM1. Conventional chromosome karyotype analysis showed abnormal clones of t(5;8)(q32;p22), and fluorescence in situ hybridization (FISH) confirmed rearrangement of the PDGFRB gene. Reverse transcription PCR (RT-PCR) and Sanger sequencing further confirmed that exon 30 of the PCM1 gene was fused with exon 11 of PDGFRB in frame, and the fusion event was accompanied by a 14 bp deletion of exon 11 of PDGFRB. Read More

View Article and Full-Text PDF

Hematological Aspects of COVID-19.

Authors:
Dafna Yahav

Acta Haematol 2022 Mar 21. Epub 2022 Mar 21.

N/A. Read More

View Article and Full-Text PDF

MiR-199a-3p Overexpression Suppressed Cell Proliferation and Sensitized Chronic Myeloid Leukaemia Cells to Imatinib by Inhibiting mTOR Signalling.

Acta Haematol 2022 Mar 21. Epub 2022 Mar 21.

Introduction: Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Drug resistance remains one of the major challenges in CML therapy. MicroRNA (miR)-199a-3p plays an important role in many tumours but has rarely been investigated in CML. Read More

View Article and Full-Text PDF

Long-term adherence to direct oral anticoagulants in patients with atrial fibrillation; a comparative cross-sectional study.

Acta Haematol 2022 Mar 18. Epub 2022 Mar 18.

Background: Long-term treatment with direct oral anticoagulants (DOAC) is required for the majority of patients with non-valvular atrial fibrillation (AF) to prevent ischemic stroke and systemic embolism. Adherence to therapy may impact clinical outcomes. Therefore, the purpose of this study was to assess the potential impact of structured follow-up on long-term adherence to DOAC therapy compared to standard care. Read More

View Article and Full-Text PDF

Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.

Acta Haematol 2022 Mar 1:1-11. Epub 2022 Mar 1.

Shanghai Institute of Hematology, Blood and Marrow Transplantation Center, Department of Hematology, Collaborative Innovation Center of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,

Introduction: The overall outcome of patients with refractory AML (rAML) remains poor. Though allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered as the only curative therapy, it is routinely recommended only for patients after remission with salvage chemotherapy.

Objective: In this study, we evaluated the impact of salvage chemotherapy or allo-HSCT on the overall outcome in rAML. Read More

View Article and Full-Text PDF

Vaccination for SARS-CoV-2 in Hematological Patients.

Acta Haematol 2022 Feb 25. Epub 2022 Feb 25.

Patients with specific hematological malignancies (HM) are at increased risk for severe disease and death from infection with SARS-CoV-2. In healthy subjects, vaccination against SARS-CoV-2 has been demonstrated to be highly effective in disease prevention, however immunocompromised patients were largely excluded from vaccine randomized controlled trials. In this review, we overview available non-randomized studies addressing effectiveness and safety of several COVID-19 vaccines in patients with HM. Read More

View Article and Full-Text PDF
February 2022

Challenges and Management of Long COVID in Individuals with Hematological Illnesses.

Acta Haematol 2022 Feb 8. Epub 2022 Feb 8.

Coronavirus disease-2019 (COVID-19) has impacted hundreds of millions of people globally, a relatively large proportion of whom continue to suffer from ongoing, sometime debilitating symptoms. This phenomenon, termed "long COVID", is difficult to diagnose and manage because of a paucity of objective findings and despite the abundance of descriptive data published so far. In this review we aimed to describe the common manifestations of long COVID, diagnostic and management challenges, and address specific aspects in hematologic patients. Read More

View Article and Full-Text PDF
February 2022

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments.

Acta Haematol 2022 Feb 8. Epub 2022 Feb 8.

Patients with hematologic malignancies are particularly vulnerable to infections due to underlying humoral and cellular immune dysfunction, cytotoxic chemotherapy regimens, advanced age, and the presence of comorbid conditions. Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has become a leading cause of death globally and has disproportionally affected this high-risk population. Here, we review the cumulative evidence demonstrating worse outcomes for patients with hematologic malignancies when compared to patients with solid tumors and the general population. Read More

View Article and Full-Text PDF
February 2022

SARS-CoV-2 Infection and Blood Safety.

Acta Haematol 2022 Feb 8. Epub 2022 Feb 8.

Since the outbreak of SARS-CoV-2, it has spread rapidly around the world and caused a serious global social crisis. During the epidemic, the blood collection and supply industry have been greatly impacted, due to the sharply dropped blood donors and transfusion transmission risk of SARS-CoV-2. Many infected individuals are asymptomatic and they may donate blood without awareness of the infection or before symptoms appear. Read More

View Article and Full-Text PDF
February 2022

Imaging of Hematological Patients in the Era of COVID-19.

Acta Haematol 2022 Jan 31. Epub 2022 Jan 31.

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulted in changes in management and imaging routines for patients with hematological malignancies. Treating physicians had to familiarize themselves with a new disease, with distinct imaging manifestations, sometimes overlapping with other infections prevalent in this patient population. In some aspects, infected hematological patients might exhibit a different disease course, and routine imaging in asymptomatic hematological patients may result in unexpected COVID-19 findings, implying covert infection, that should be further explored. Read More

View Article and Full-Text PDF
January 2022

Tocilizumab Treatment Effect on Iron Homeostasis in Severe COVID-19 Patients.

Acta Haematol 2022 Jan 31. Epub 2022 Jan 31.

Background: Tocilizumab has been proposed as an effective treatment for severe COVID-19. We aimed to investigate whether tocilizumab administration is associated with increased availability of serum iron which may possibly be associated with adverse effects on clinical outcomes.

Methods: We performed an observational, retrospective cohort study. Read More

View Article and Full-Text PDF
January 2022

Evaluation of Activated Carbon Treatment on Overcoming the Interference of Rivaroxaban on the Detection of Functional Lupus Anticoagulant.

Acta Haematol 2022 Jan 31. Epub 2022 Jan 31.

Objective: To study the role of activated carbon in eliminating the interference of rivaroxaban in the detection of lupus anticoagulants (LA).

Methods: Normal pooled plasma (NPP) was obtained as Group N1, and Group N2 took 1ml plasma from N1 and added activated carbon; Group N3 was prepared by mixing normal plasma with rivaroxaban, and Group N3 was treated with activated carbon according to our procedure, as Group N4. Plasma from 22 patients was collected before and 6-12 hours after rivaroxaban therapy, described as group P1 and group P2 respectively, and 1ml plasma was taken from Group P2 and treated with activated carbon, as Group P3. Read More

View Article and Full-Text PDF
January 2022

Distinct Mechanisms of IgM-Antibody-Mediated Acquired von Willebrand Syndrome and Successful Treatment with Recombinant von Willebrand Factor in One Patient.

Acta Haematol 2022 Jan 27. Epub 2022 Jan 27.

Acquired von Willebrand Syndrome (AVWS) is a rare coagulation disorder which can be associated with IgM-paraproteinaemia. Recently, recombinant von Willebrand factor (rVWF) has become available for the treatment of bleedings in patients with inherited von Willebrand disease, but experience in patients with AVWS is limited. We report on two patients with AVWS with underlying IgM paraproteinaemia with distinct underlying pathomechanisms. Read More

View Article and Full-Text PDF
January 2022

Threshold of Serum Ferritin to Discriminate against Those at Greater Risk of Platelet Increase during Treatment with Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor.

Acta Haematol 2022 Jan 20. Epub 2022 Jan 20.

Introduction: Hypoxia-inducible factor prolyl hydroxylase domain inhibitors (HIF-PHI) are a new treatment for renal anemia. HIF-PHI is believed to increase iron usage to improve availability of iron for erythropoiesis. Therefore, there is concern that HIF-PHI might be prone to iron deficiency and that thrombosis might be induced by increased platelet and transferrin levels due to this iron deficiency. Read More

View Article and Full-Text PDF
January 2022

Neutropenia in the First Cycle of Consolidation Chemotherapy with High-Dose Cytarabine Is Not Associated with the Incidence of Relapse in Adult Acute Myeloid Leukemia Patients in First Complete Remission.

Acta Haematol 2022 Jan 19. Epub 2022 Jan 19.

Background: It has been reported that prolonged neutropenia during post-remission chemotherapy is associated with a reduced risk of disease relapse in pediatric acute myeloid leukemia (AML) patients.

Methods: We retrospectively reviewed the charts of adult AML patients in first complete remission (CR1) who underwent consolidation chemotherapy with high-dose cytarabine. Those receiving allogeneic hematopoietic cell transplantation in CR1 were excluded. Read More

View Article and Full-Text PDF
January 2022

The Prognostic Impact of MYC Gene-Related Abnormalities on Multiple Myeloma Outcome through Fluorescence in situ Hybridization Analysis.

Acta Haematol 2022 Jan 11. Epub 2022 Jan 11.

Introduction: Chromosomal abnormalities (CAs) have been identified as important factors in determining the biological features and prognostic value of multiple myeloma (MM). MYC gene-related abnormalities (MYC GAs) are one of the CAs, but its unfavorable impact has not been fully investigated in daily clinical practice.

Methods: This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute. Read More

View Article and Full-Text PDF
January 2022

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response.

Acta Haematol 2022 Jan 11. Epub 2022 Jan 11.

Introduction: Although splenectomy has long been second-line option for immune thrombocytopenia (ITP) patients, an indicator that reliably predicts the efficacy of splenectomy is still being explored. We investigated the treatment outcomes of splenectomy as a second-line therapy for relapsed/refractory ITP according to first-line intravenous immunoglobulin (IVIG) responses.

Methods: Fifty-two adult patients treated with splenectomy as second-line therapy for ITP between 2009 and 2019 were included, and they were classified according to first-line IVIG responses (no response to IVIG: non-responders; only transient IVIG response shorter than 4 weeks: poor responders; IVIG response for a longer period; stable responders). Read More

View Article and Full-Text PDF
January 2022

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.

Acta Haematol 2022 Jan 10:1-5. Epub 2022 Jan 10.

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Ruxolitinib is an FDA-approved treatment of intermediate- and high-risk myelofibrosis. In the phase 3 COMFORT studies, ruxolitinib reduced spleen volume in patients with myelofibrosis, with a median time to response of 3 months. However, nearly 20% of patients discontinued by month 4 with few treatment options available following discontinuation of ruxolitinib treatment. Read More

View Article and Full-Text PDF
January 2022

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany.

Acta Haematol 2021 Dec 27. Epub 2021 Dec 27.

Introduction: The effectiveness and safety of romiplostim were evaluated by immune thrombocytopenia (ITP) phase (newly diagnosed/persistent/chronic) at romiplostim initiation.

Methods: Post hoc analysis of a prospective, German, multicentre, observational study in adults with ITP who received ≥1 dose of romiplostim. Follow-up data were collected for ≤2 years. Read More

View Article and Full-Text PDF
December 2021